Some are ready to call it quits on the cannabis market.
But the Green Revolution has only just gotten started.
CSE:TTT; OTC:TTTSF). is one of them.’ data-reactid=”15″>There are plenty of opportunities for investors looking to cash in on the cannabis boom—and TruTrace Technologies (CSE:TTT; OTC:TTTSF). is one of them.
The genius of TruTrace is simple – it’s taking tech solutions to the problems of the still under-developed, under-supported cannabis supply chain.
And where other cannabis plays have focused on production – which firms have the most product, the lowest prices, the biggest chunk of market – TruTrace hopes to make a splash by tackling the issues surrounding the emergence of a new market—one that could be worth billions of dollars.
We’ve all read the headlines.
But it could be much, much bigger.
CSE:TTT; OTC:TTTSF) could be a better fit—because it’s going where no other cannabis firm has ever gone before.’ data-reactid=”60″>TruTrace (CSE:TTT; OTC:TTTSF) could be a better fit—because it’s going where no other cannabis firm has ever gone before.
TruTrace is unique. It doesn’t deal in cannabis – it deals in information. Big Data.
The company has two businesses.
First, there’s the company’s supply chain innovation: indexing and searching through a huge database that includes information from across the cannabis world.
Right now, every jurisdiction manages cannabis a little differently. The legal market is tightly regulated.
The StrainSecure platform incorporates elements of social media. Customers have the chance to verify and critique strains included in the system, offering greater opportunities for brand engagement.
The platform also allows retailers to engage customers and build brand loyalty in new ways through the StrainSecure QR Code.
(Click to enlarge)
Right now, this system is in its early stages – but TruTrace has plans for rapid growth.
It works like this: anyone who wants to engage the cannabis community can register on the StrainSecure service, providing information to create a profile.
That participant – be it a seed farmer, a grower, a regulator or a producer – can then take part in the verification and testing process, ensuring that the information contained within StrainSecure is accurate.
(Click to enlarge)
The service is specifically geared towards the medical cannabis market – allowing hospitals, doctors, patients and companies access to key information regarding cannabis products.
(Click to enlarge)
Walgreens and CVS, both of which are expanding into the CBD market.’ data-reactid=”161″>From there, it hopes to move onward to the United States, where cannabis is regulated in more than a dozen states. In California and Washington DC, where cannabis is decriminalized, TruTrace will target major distributors of CBD and cannabis products—including Walgreens and CVS, both of which are expanding into the CBD market.
But buzz is starting to build.‘ data-reactid=”184″>But buzz is starting to build.
StrainSecure has plans for expansion in 2019 and 2020.
CSE:TTT; OTC:TTTSF) is sitting on an idea potentially worth a fortune, for a market that has only just begun its meteoric growth.’ data-reactid=”188″>Between the supply chain and product verification elements, TruTrace (CSE:TTT; OTC:TTTSF) is sitting on an idea potentially worth a fortune, for a market that has only just begun its meteoric growth.
Investors can’t afford to let this one sail by.
Auxly is an up-and-comer in the marijuana industry, with a growing presence in Eastern Canada. The company, formerly known as Cannabis Wheaton, the streaming company operates with a unique spin, focusing on its investments and partnerships within the space.
Some investors are bullish on Auxly due to its rapid rate of growth. And its recent strategic partnership with Atlantic Cultivation solidifies that stance.
The $2.5 million deal gives Auxly a 50 percent equity stake in Atlantic, in addition to a right-to-purchase up to 30 percent of dried cannabis and cannabis trim at Atlantic’s Newfoundland and Labrador facilities.
green light from Canadian regulatory officials to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in the country.’ data-reactid=”198″>In addition to its production commitments, however, Emerald Health has also just received the green light from Canadian regulatory officials to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in the country.
Hexo, previously Hydropothecary, is making some major moves in the cannabis industry. The company, which is engaged in the production, distribution and marketing of cannabis and cannabis products, has secured a huge deal with international beverage giant Molson Coors.
The joint venture signifies a new era in recreational marijuana, bringing two heavyweight industries together under one roof.
noted, “My team and I have spent the past year finding a partner that shares our vision, values and passion for cannabis. The team at Supreme Cannabis understands the importance of high quality cannabis and how to produce high quality cannabis at scale.”’ data-reactid=”206″>Wiz Khalifa noted, “My team and I have spent the past year finding a partner that shares our vision, values and passion for cannabis. The team at Supreme Cannabis understands the importance of high quality cannabis and how to produce high quality cannabis at scale.”
Valued at more than $1.65 billion, with 800 employees and 18 licensed marijuana facilities in California, Nevada and New York, MedMen is a large U.S. marijuana firm and one of the biggest dispensaries around. Its stores are affectionately known as the “Apple Stores of weed,” and the company has done well marketing marijuana in the three U.S. states.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.